Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Complement; Plasma; Eculizumab; Properdin;
مقالات ISI Eculizumab (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Eculizumab; Complement; Complement inhibitors; Systemic lupus erythematosus; Lupus nephritis; Treatment; Eculizumab;
Keywords: Eculizumab; Complement; eculizumab; factor H; factor I; hemolytic uremic syndrome; membrane cofactor protein; thrombomodulin; transplantation;
SÃndrome hemolÃtico urémico: estado actual
Keywords: Eculizumab; SÃndrome hemolÃtico urémico; Eculizumab; VÃa alternativa del complemento; Anemia hemolÃtica microangiopática; Haemolytic uremic syndrome; Eculizumab; Alternative complement pathway; Microangiopathic haemolytic anaemia;
Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy
Keywords: Eculizumab; C3 glomerulopathy (C3G); membranoproliferative glomerulonephritis (MPGN); complement; eculizumab; anti-C5 monoclonal antibody; rapidly progressive glomerulonephritis; pediatric; C3 nephritic factor (C3Nef); kidney biopsy; proteinuria; clinical response; c
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli
Keywords: Eculizumab; Anakinra; Brodalumab; Canakinumab; Eculizumab; Infection; Ixekizumab; Prevention; Rilonacept; Secukinumab; Tocilizumab;
Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses
Keywords: Eculizumab; Complement; Eculizumab; C5; C5a; Neoepitope;
Microangiopathie thrombotique secondaire à la gemcitabine : peut-on améliorer le dépistage et la prise en charge ?
Keywords: Eculizumab; Dépistage; Ãculizumab; Gemcitabine; Microangiopathie thrombotique; Eculizumab; Gemcitabine; Screening; Thrombotic microangiopathy;
Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine
Keywords: Eculizumab; Drug-induced thrombotic microangiopathy; Eculizumab; Hemolytic uremic syndrome; Pancreatic cancer; Toxicity;
C3 nephritic factors: AÂ changing landscape
Keywords: Eculizumab; C3 nephritic factor; alternative complement activation; membranoproliferative glomerulonephritis; C3 glomerulopathy; dense-deposit disease; partial lipodystrophy; eculizumab;
MicroangiopatÃa trombótica secundaria y eculizumab: una opción terapéutica razonable
Keywords: Eculizumab; MicroangiopatÃas trombóticas secundarias; Activación del complemento; Eculizumab; Secondary thrombotic microangiopathies; Complement activation; Eculizumab;
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
Keywords: Eculizumab; Complement activation; C5a blockade; Trypsin; Thrombin; Eculizumab; aHUS; atypical hemolytic uremic syndrome; APH50; 50% haemolytic complement activity of alternative pathway; C3N; C3 glomerulonephritis; CH50; 50% haemolytic complement activity of classic
Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody
Keywords: Eculizumab; Postinfectious glomerulonephritis (PIGN); crescentic PIGN; terminal complement pathway blockade; anti-C5 monoclonal antibody; eculizumab; acute kidney injury; anti-factor H autoantibody; complement; CFH; kidney function; renal biopsy; pediatric; case re
Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action
Keywords: Eculizumab; aHUS; atypical hemolytic and uremic syndrome; C5; complement protein C5; CDR; complementarity determining region; CVF; cobra venom factor; DMSO; dimethylsulfoxyde; ECZ; eculizumab; Fab; fragment antigen binding; Fv; fragment variable; mAb; monoclonal anti
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
Keywords: Eculizumab; Thrombotic microangiopathy; Eculizumab; CH50; Membrane attack complex; Complement; sC5b-9;
Complement inhibition in C3 glomerulopathy
Keywords: Eculizumab; Membranoproliferative glomerulonephritis; C3 glomerulopathy; Complement; Dense deposit disease; C3 glomerulonephritis; Eculizumab
Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Thrombotic microangiopathies; Complement activation; Terminal complement complex; Eculizumab;
Syndrome hémolytique et urémique atypique confondu avec un syndrome de Goodpasture : à propos d’un cas
Keywords: Eculizumab; Anticorps anti-MBG; Échanges plasmatiques; Éculizumab; Hémorragie intra-alvéolaire; Syndrome hémolytique et urémique atypique; Syndrome pneumo-rénalAnti-GBM antibodies; Atypical hemolytic uremic syndrome; Eculizumab; Intra-alveolar hemorrhage; Plasma exch
Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy
Keywords: Eculizumab; C3 glomerulopathy (C3G); C5b-9 deposits; complement; complement alternative pathway; eculizumab; rapidly progressing glomerulonephritis; acute kidney injury (AKI);
Síndrome hemolítico urémico atípico
Keywords: Eculizumab; Síndrome hemolítico urémico atípico; Vía alternativa del complemento; Tratamiento plasmático; EculizumabAtypical hemolytic uremic syndrome; Alternative pathway of complement system; Plasma therapy; Eculizumab
La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques
Keywords: Eculizumab; Microangiopathie thrombotique; Purpura thrombotique thrombocytopénique; Syndrome hémolytique et urémique; Rituximab; Ãculizumab; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Haemolytic and uremic syndrome; Rituximab; Eculizumab;
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury
Keywords: Eculizumab; Thrombotic microangiopathy; TA-TMA; Kidney disease; Complement activation; Hematopoietic cell transplant; Eculizumab;
Shiga Toxin Associated Hemolytic Uremic Syndrome
Keywords: Eculizumab; Thrombotic microangiopathy; Shiga toxin; Complement; Eculizumab;
Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso
Keywords: Eculizumab; Síndrome hemolítico urémico atípico; Eculizumab; Complemento; Microangiopatía trombóticaAtypical haemolytic uraemic syndrome; Eculizumab; Complement; Thrombotic microangiopathy
Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency
Keywords: Eculizumab; Hemolytic uremic syndrome (HUS); cobalamin; eculizumab; MMACHC (methylmalonic aciduria and homocystinuria type C protein); cobalamin C disease; chronic kidney failure;
Mikroangiopatie zakrzepowe: nowe spojrzenie na patofizjologiÄ i terapiÄ
Keywords: Eculizumab; mikroangiopatia zakrzepowa; zespóÅ hemolityczno-mocznicowy; ekulizumab; Thrombotic microangiopathy; Hemolytic uremic syndrome; Eculizumab;
ReviewComplement therapy in atypical haemolytic uraemic syndrome (aHUS)
Keywords: Eculizumab; Eculizumab; Haemolytic Uraemic Syndrome; Treatment; Complement;
Eculizumab : efficacité d'un schéma court dans le traitement d'un syndrome hémolytique et urémique atypique d'origine indéterminée
Keywords: Eculizumab; syndrome hémolytique et urémique atypique; eculizumab; schéma court; atypical haemolytic uremic syndrome; eculizumab; shortened dosing schedule; ADAMTS 13; métalloprotéase clivant le facteur de Willebrand; AMM; autorisation de mise sur le marché; EP
Learnings from over 25 years of PNH experience: The era of targeted complement inhibition
Keywords: Eculizumab; Paroxysmal nocturnal haemoglobinuria (PNH); Chronic uncontrolled complement activation; Eculizumab; Thrombosis; Premature mortality; Nitric oxide scavenging
Syndrome hémolytique et urémique à Escherichia coli : quels enseignements tirer après l’épidémie européenne de 2011 ?
Keywords: Eculizumab; Complément; Échanges plasmatiques; Eculizumab; Escherichia coli; O104:H4; Shigatoxine; Syndrome hémolytique et urémiqueComplement; Eculizumab; Escherichia coli; Hemolytic and uremic syndrome; O104:H4; Plasmapheresis; Shigatoxin
Treatment of Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathies: A Focus on Eculizumab
Keywords: Eculizumab; Thrombotic microangiopathy; complement; atypical hemolytic uremic syndrome; eculizumab;
Síndrome hemolítico urémico infantil
Keywords: Eculizumab; Escherichia coli productora de toxina shiga; Streptococcus pneumoniae; Aciduria metilmalónica; Síndrome hemolítico urémico atípico; Complemento; Eculizumab
Enterohemorrhagic Escherichia coli Infections and the Hemolytic-Uremic Syndrome
Keywords: Eculizumab; Escherichia coli O157:H7; Escherichia coli O104:H4; Shiga toxin; Enterohemorrhagic Escherichia coli; Hemolytic-uremic syndrome; Eculizumab;
Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome in Infants
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; eculizumab; infant;
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Keywords: Eculizumab; Paroxysmal nocturnal hemoglobinuria; Complement alternative pathway; Complement component 3; Complement component 5; Eculizumab; TT30; C3-targeted therapy
Complement-mediated injury and protection of endothelium: Lessons from atypical haemolytic uraemic syndrome
Keywords: Eculizumab; AP; alternative pathway; CPN; carboxypeptidase N; CP; classical pathway; CR1, CD35; complement receptor 1; ciGEC; conditionally immortalised glomerular endothelial cells; CRP; C-reactive protein; DAF, CD55; decay accelerating factor; HUS; haemolytic uraem
Conclusions et perspectives en transplantation rénale pédiatrique
Keywords: Eculizumab; Belatacept; Bortezomide; Eculizumab; Enfant; Transplantation rénale; Vaccin EBVBelatacept; Bortezomide; Eculizumab; EBV vaccine; Renal transplantation; Pediatrics
Management of refractory cases of catastrophic antiphospholipid syndrome
Keywords: Eculizumab; Catastrophic antiphospholipid syndrome; Refractory; Anticardiolipin antobodies; Lupus anticoagulant; Rituximab; Defibrotide; Eculizumab
Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; eculizumab; factor H; renal transplantation;
Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab
Keywords: Eculizumab; PNH; Pregnancy; Eculizumab
Bone Marrow Failure Syndromes: Paroxysmal Nocturnal Hemoglobinuria
Keywords: Eculizumab; Hemolysis; Aplastic anemia; Myelodysplasia; Bone marrow failure; Bone marrow transplant; Eculizumab
Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria
Keywords: Eculizumab; Paroxysmal nocturnal hemoglobinuria; PIG-A; Nitric oxide; Eculizumab; FLAER; Proaerolysin; Complement; Glycosylphosphatidylinositol anchored protein
New approaches to the treatment of glomerular diseases
Keywords: Eculizumab; glomerular disease; mycophenolate; rituximab; sirolimus; calcineurin inhibitors; eculizumab;